On July 23 and 24, 2026, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) convenes at the White Oak campus in Silver Spring, Maryland to review whether seven peptides belong on the Section 503A Bulk Drug Substances List. This is the single biggest peptide-policy event of the year, and we’re tracking it here as it happens.
This page will be updated with the committee’s recommendations as soon as they’re available. Bookmark it — we’re keeping it as the permanent reference point for where each peptide stands.
What’s Actually Being Voted On
The committee is reviewing seven bulk drug substances for inclusion on the 503A list — the list that gives licensed compounding pharmacies legal authority to prepare a substance against an individual patient prescription. Being added to this list does not mean a peptide becomes FDA-approved; it means licensed pharmacies gain a legal pathway to compound it once the FDA completes formal rulemaking, a process that historically takes six to eighteen months after a favorable recommendation.
| Day | Substances Reviewed |
|---|---|
| July 23 | BPC-157, KPV, TB-500, MOTS-c (free base and acetate forms) |
| July 24 | Emideltide (DSIP), Semax, Epitalon (free base and acetate forms) |
The Detail Most Coverage Is Getting Wrong
All seven substances already came off the FDA’s Category 2 “do not compound” list on April 23, 2026. That reclassification is what teed up this review in the first place — it did not itself restore legal compounding. So this meeting is not a re-ban risk. It’s an upside vote: the question is whether a new legal compounding channel opens, not whether an existing one closes.
It’s also worth knowing that FDA staff briefing documents published ahead of the meeting reportedly raise concerns about characterization, limited human safety data, and unassessed immunogenicity risk for several of the substances under review — a signal that the panel discussion may be more cautious than headline-driven anticipation suggests. PCAC recommendations are advisory only; the FDA is not bound to follow them.
What Happens After the Vote
- Favorable recommendation: FDA begins formal rulemaking to add the substance to the 503A bulks list. This does not create immediate access — expect a multi-month to multi-year process before compounding pharmacies can legally prepare it.
- Unfavorable recommendation: The current nomination generally ends, though substances can be re-nominated in a future cycle. The peptide remains off Category 2 but without a bulks-list pathway, meaning research-use channels remain the only current option.
- Deferred/mixed: The most likely realistic outcome per industry trackers — a split result where one or two substances get a favorable nod and the rest are deferred pending more data.
Where Each Peptide Stands Right Now
For research-use context on any of these compounds while the process plays out, see our individual profiles below.